Last week, the Competition Commissioner imposed an administrative fine on MBI Pharma Ltd., drugs importer for excessive pricing of a drug intended for the treatment of a rare metabolic condition known as Cerebrotendinous Xanthomatosis (CTX).

The company was fined NIS 8 million, and two senior executives were fined NIS 614,000 each. This is the first time that the Competition Commissioner in Israel has actually taken steps against monopoly excessive prices.

Read more here >>